Literature DB >> 29622888

CD38-Negative Myeloma with Anaplastic Morphology at Presentation: A Case Report.

Neha Singh1, Narendra Agrawal2, Anurag Mehta1, Ajit Panaych1, Radhika Sekhri1.   

Abstract

Entities:  

Year:  2017        PMID： 29622888      PMCID： PMC5884992          DOI： 10.1007/s12288-017-0880-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  8 in total

1.  Plasma cell myeloma with anaplastic transformation.

Authors:  Shenon Sethi; Ira Miller
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

Review 2.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

3.  Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.

Authors:  Mikiko Ise; Keiko Matsubayashi; Hideki Tsujimura; Kyoya Kumagai
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-02-27

4.  Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.

Authors:  Samantha Reid; S Yang; R Brown; K Kabani; E Aklilu; P J Ho; N Woodland; D Joshua
Journal:  Int J Lab Hematol       Date:  2010-12       Impact factor: 2.877

Review 5.  The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Authors:  Régis Bataille; Gaëtan Jégo; Nelly Robillard; Sophie Barillé-Nion; Jean-Luc Harousseau; Philippe Moreau; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2006-09       Impact factor: 9.941

6.  Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.

Authors:  T E Witzig; T Kimlinger; M Stenson; T Therneau
Journal:  Leuk Lymphoma       Date:  1998-09

7.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Authors:  Yawara Kawano; Shiho Fujiwara; Naoko Wada; Mikiko Izaki; Hiromichi Yuki; Yutaka Okuno; Kenichi Iyama; Hiroshi Yamasaki; Akira Sakai; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2012-07-04       Impact factor: 5.650
  8 in total
  6 in total

1.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

2.  Macrophage activation syndrome revealing Hodgkin's lymphoma: a case report.

Authors:  Mustapha Mechtoune; Rajae Tissir; Ilias Tazi
Journal:  Pan Afr Med J       Date:  2021-02-03

3.  Anaplastic multiple myeloma with MYC rearrangement.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Ko Hashimoto; Fumiyoshi Fujishima; Ryo Ichinohasama; Hideo Harigae
Journal:  Leuk Res Rep       Date:  2021-12-27

4.  CD38 - Negative Anaplastic Plasma Cell Myeloma: A Rare Case Report.

Authors:  An Thi Vinh Do; Le Lan Anh
Journal:  Cureus       Date:  2022-01-03

5.  Anaplastic Multiple Myeloma: Case Series and Literature Review.

Authors:  Jian Wu; Emily Chu; Cristiana Costa Chase; Taewoong Choi; Cristina Gasparetto; Ken Young; Yubin Kang
Journal:  Asploro J Biomed Clin Case Rep       Date:  2022-01-15

6.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.